Meeting
2017 ASCO Annual Meeting
A phase III study of rovalpituzumab tesirine maintenance therapy following first-line platinum-based chemotherapy in patients with extensive disease small cell lung cancer (ED SCLC).
Authors
Philip B. Komarnitsky
AbbVie Inc., Cambridge, MA
Philip B. Komarnitsky , Ho-Jin Lee , Manan Shah , Shekman Wong , Sanja Gauthier , Juliann Dziubinski , Stacy Osbaugh , Fan Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03033511
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS8583)
DOI
10.1200/JCO.2017.35.15_suppl.TPS8583
Abstract #
TPS8583
Poster Bd #
315a
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Randomized phase III trial in extensive-disease small cell lung cancer comparing first-line etoposide to topotecan in combination with platinum.
First Author: Morten Mau-Soerensen
Poster
2017 ASCO Annual Meeting
A phase 3, randomized study of first-line durvalumab (D) ± tremelimumab (T) + platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): Caspian.
First Author: Luis G. Paz-Ares
Poster
2013 ASCO Annual Meeting
A multicenter phase III randomized double-blind placebo controlled trial of pravastatin added to first-line standard chemotherapy in patients with small cell lung cancer (SCLC).
First Author: Michael Seckl
Poster
2013 ASCO Annual Meeting
CA184-156: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus placebo plus EP in patients (Pts) with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC).
First Author: Joachim Von Pawel